CL2024001679A1 - Formas en estado sólido de un inhibidor de fgfr - Google Patents

Formas en estado sólido de un inhibidor de fgfr

Info

Publication number
CL2024001679A1
CL2024001679A1 CL2024001679A CL2024001679A CL2024001679A1 CL 2024001679 A1 CL2024001679 A1 CL 2024001679A1 CL 2024001679 A CL2024001679 A CL 2024001679A CL 2024001679 A CL2024001679 A CL 2024001679A CL 2024001679 A1 CL2024001679 A1 CL 2024001679A1
Authority
CL
Chile
Prior art keywords
solid state
state forms
fgfr inhibitor
forms
pyrrolidin
Prior art date
Application number
CL2024001679A
Other languages
English (en)
Spanish (es)
Inventor
W Kaldor Stephen
Tyhonas John
Kanouni Toufike
Kania Robert
M Cox Jason
P Reddy Jayachandra
Phimister Andrew
Chopade Shubham
Pandey Preetanshu
Original Assignee
Kinnate Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinnate Biopharma Inc filed Critical Kinnate Biopharma Inc
Publication of CL2024001679A1 publication Critical patent/CL2024001679A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
CL2024001679A 2021-12-08 2024-06-06 Formas en estado sólido de un inhibidor de fgfr CL2024001679A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163287212P 2021-12-08 2021-12-08

Publications (1)

Publication Number Publication Date
CL2024001679A1 true CL2024001679A1 (es) 2024-11-29

Family

ID=86731361

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001679A CL2024001679A1 (es) 2021-12-08 2024-06-06 Formas en estado sólido de un inhibidor de fgfr

Country Status (12)

Country Link
US (1) US20250059170A1 (enExample)
EP (1) EP4444302A4 (enExample)
JP (1) JP2024542840A (enExample)
KR (1) KR20240119095A (enExample)
CN (1) CN118804748A (enExample)
AU (1) AU2022407440A1 (enExample)
CA (1) CA3239792A1 (enExample)
CL (1) CL2024001679A1 (enExample)
IL (1) IL313359A (enExample)
MX (1) MX2024006933A (enExample)
TW (1) TW202332432A (enExample)
WO (1) WO2023107980A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529867A (ja) 2020-06-05 2023-07-12 キネート バイオファーマ インク． 線維芽細胞増殖因子受容体キナーゼの阻害剤
KR20240115884A (ko) * 2021-12-08 2024-07-26 킨네이트 바이오파마 인크. Fgfr 키나제 억제제를 이용하는 암의 치료

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015008844A1 (ja) * 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
CN107840842A (zh) * 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
WO2020236524A1 (en) * 2019-05-17 2020-11-26 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
JP2023529867A (ja) * 2020-06-05 2023-07-12 キネート バイオファーマ インク． 線維芽細胞増殖因子受容体キナーゼの阻害剤

Also Published As

Publication number Publication date
WO2023107980A1 (en) 2023-06-15
US20250059170A1 (en) 2025-02-20
KR20240119095A (ko) 2024-08-06
CN118804748A (zh) 2024-10-18
EP4444302A1 (en) 2024-10-16
EP4444302A4 (en) 2025-09-03
AU2022407440A1 (en) 2024-06-20
MX2024006933A (es) 2024-08-26
TW202332432A (zh) 2023-08-16
IL313359A (en) 2024-08-01
CA3239792A1 (en) 2023-06-15
JP2024542840A (ja) 2024-11-15

Similar Documents

Publication Publication Date Title
SA522441639B1 (ar) Egfr مثبطات تفارغية وطرق استخدامها
EP4360713A3 (en) Quinazoline derivatives as antitumor agents
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
MX2024012801A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
CL2022000998A1 (es) Inhibidores de las cinasas raf
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
DOP2019000250A (es) Composicion farmaceutica que comprende selexipag
MX2022001562A (es) Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
CO2022018806A2 (es) Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblastos
JOP20210269A1 (ar) تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها
MX2024002391A (es) Inhibidores de indolina de kif18a.
EA201790950A1 (ru) Способы и композиции, в частности, для лечения синдрома дефицита внимания
CO2024009144A2 (es) Inhibidores de cinasa met
GEAP202215599A (en) Boron containing pde4 inhibitors
CL2025001938A1 (es) Formas cristalinas de inhibidores del inflamasoma nlrp3, procesos químicos y compuestos químicos.
SA523440574B1 (ar) مثبطات إنترليوكين-17
MX2024006933A (es) Formas en estado solido de un inhibidor de fgfr.
JOP20220355A1 (ar) مثبطات rip1k
PE20081308A1 (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.